Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.16 | -0.48% | -0.02 |
Earnings due: May 3
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical AQST trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | -0.48% | |
| Spinning Top | Other | -0.48% | |
| Wide Bands | Range Expansion | -0.48% | |
| Oversold Stochastic | Weakness | -0.48% | |
| Outside Day | Range Expansion | -2.35% | |
| Wide Bands | Range Expansion | -2.35% | |
| Oversold Stochastic | Weakness | -2.35% | |
| Wide Bands | Range Expansion | 6.12% | |
| Down 3 Days in a Row | Weakness | 6.12% | |
| Down 4 Days in a Row | Weakness | 6.12% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 12 minutes ago |
| Rose Above 10 DMA | 30 minutes ago |
| Down 1% | 30 minutes ago |
| Up 1% | 30 minutes ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/03/2021
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Diseases Drugs Opioid Psychoactive Drugs Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Opioids Seizure Xone Seizures Gabaa Receptor Positive Allosteric Modulators Lactams Parkinson’s Disease Neuroendocrine Tumor Neuroendocrine Tumors Buprenorphine/Naloxone Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.465 |
| 52 Week Low | 3.67 |
| Average Volume | 904,873 |
| 200-Day Moving Average | 5.88 |
| 50-Day Moving Average | 4.93 |
| 20-Day Moving Average | 4.51 |
| 10-Day Moving Average | 4.28 |
| Average True Range | 0.35 |
| ADX | 16.38 |
| +DI | 17.94 |
| -DI | 24.20 |
| Chandelier Exit (Long, 3 ATRs ) | 4.37 |
| Chandelier Exit (Short, 3 ATRs ) | 4.92 |
| Upper Bollinger Band | 5.25 |
| Lower Bollinger Band | 3.78 |
| Percent B (%b) | 0.27 |
| BandWidth | 32.52 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.20 |
| MACD Histogram | -0.031 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.57 | ||||
| Resistance 3 (R3) | 4.58 | 4.47 | 4.51 | ||
| Resistance 2 (R2) | 4.47 | 4.37 | 4.46 | 4.48 | |
| Resistance 1 (R1) | 4.32 | 4.31 | 4.27 | 4.31 | 4.46 |
| Pivot Point | 4.21 | 4.21 | 4.18 | 4.20 | 4.21 |
| Support 1 (S1) | 4.06 | 4.11 | 4.01 | 4.05 | 3.90 |
| Support 2 (S2) | 3.95 | 4.05 | 3.94 | 3.88 | |
| Support 3 (S3) | 3.80 | 3.95 | 3.86 | ||
| Support 4 (S4) | 3.79 |
